Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure   These findings were observed in a Phase 3 clinical trial conducted by Glenmark Pharmaceuticals and has been published by the globally reputed, peer reviewed International Journal of Infectious Diseases.   Mumbai, India; November 23, 2020: The oral antiviral medication Favipiravir, that prevents the replication phase of the virus life-cycle, leads to significant improvement in clinical cure